GDC 0994

Drug Profile

GDC 0994

Alternative Names: GDC-0994; RG-7842

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Genentech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Dec 2016 Genentech completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT02457793)
  • 29 Nov 2016 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top